Search for: "Amgen Inc"
Results 201 - 220
of 702
Sort by Relevance
|
Sort by Date
14 Dec 2017, 9:11 pm
Amgen Inc., the Supreme Court handed down its interpretation of the Biologics Price Competition and Innovation Act ("BPCIA") for the approval of biosimilar drugs. [read post]
19 Nov 2017, 9:05 pm
Noonan -- Last month, the Federal Circuit rendered a decision in Amgen Inc. v. [read post]
14 Nov 2017, 3:04 pm
Amgen Inc., 137 S. [read post]
17 Oct 2017, 6:09 pm
Judge Robinson had concluded that the patent was valid, and applied the test articulated in eBay Inc. v. [read post]
6 Oct 2017, 2:34 pm
CAFC holds that later-developed antibody species may be evidence that a claimed antibody genus is invalid for lack of written description, and casts doubt on the “antibody exception” Amgen Inc. v. [read post]
6 Oct 2017, 2:34 pm
CAFC holds that later-developed antibody species may be evidence that a claimed antibody genus is invalid for lack of written description, and casts doubt on the “antibody exception” Amgen Inc. v. [read post]
6 Oct 2017, 8:20 am
” Genentech, Inc. v. [read post]
21 Aug 2017, 6:14 pm
Amgen, Inc. v. [read post]
18 Aug 2017, 2:15 am
Amgen Inc. v. [read post]
18 Aug 2017, 2:15 am
Amgen Inc. v. [read post]
16 Aug 2017, 8:21 am
Amgen, Inc., 137 S. [read post]
11 Aug 2017, 8:00 am
Amgen, Inc. [read post]
11 Aug 2017, 6:06 am
” Order, Amgen, Inc. v. [read post]
10 Aug 2017, 9:58 pm
" trilogy of BPCIA Federal Circuit cases, the Court in Amgen Inc. v. [read post]
26 Jul 2017, 3:49 am
As explained in paragraph 42 of this judgment, in paragraph 37 of Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9, Lord Hoffmann explained that the doctrine of equivalents had been developed in the United States. [read post]
26 Jul 2017, 3:49 am
As explained in paragraph 42 of this judgment, in paragraph 37 of Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9, Lord Hoffmann explained that the doctrine of equivalents had been developed in the United States. [read post]
16 Jun 2017, 9:44 am
., Inc. in Greener Synthetic Pathways -- Letermovir: A Case Study in State-of-the-Art Approaches to Sustainable Commercial Manufacturing Processes in the Pharmaceutical Industry; Amgen Inc. and Bachem in Greener Reaction Conditions -- Green Process for Commercial Manufacture of Etelcalcetide Enabled by Improved Technology for Solid Phase Peptide Synthesis; The Dow Chemical Company and Papierfabrik August Koehler SE in Designing Greener Chemicals --… [read post]
15 Jun 2017, 10:00 pm
Amgen Inc., which involved a case emerging out of the Biologics Price Competition and Innovation Act. [read post]
15 Jun 2017, 2:09 pm
In SANDOZ INC. v. [read post]
15 Jun 2017, 2:09 pm
In SANDOZ INC. v. [read post]
